VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine®. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted. In addition, all major vendors for the study have now been chosen. CEL-SCI expects to enroll the first patient in the study during the third quarter of 2010.
